First-ever qualified Parkinson's biomarker is vital step toward improved clinical trials

(Critical Path Institute (C-Path)) The Critical Path Institute's (C-Path) Critical Path for Parkinson's Consortium (CPP), in partnership with Parkinson's UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich Parkinson's clinical trials. The purpose of this enrichment biomarker, is to serve as a measurement that can be used to select people with Parkinson's who are most suitable to take part in clinical trials.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news